{"schema_version":"secwatch.filing_event.v1","accession":"0000849146-24-000048","form_type":"8-K","ticker":"LFVN","cik":"0000849146","company_name":"Lifevantage Corp","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.137003+00:00","generated_at":"2026-06-03T01:18:25.637031+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"LifeVantage Q3 revenue falls 10.2% to $48.2M; guidance cut; adjusted EBITDA up 55%","bullets":["Revenue $48.2M, down 10.2% YoY; Americas -5.9%, Asia/Pacific & Europe -22.4% (constant currency -16.1%).","GAAP EPS $0.13, adjusted EPS $0.21 vs $0.08 a year ago; adjusted EBITDA $5.1M, up 54.7%.","Fiscal 2024 revenue guidance lowered to $202-205M from $207-213M; adjusted EBITDA guidance unchanged at $16-18M.","Declared $0.04/share cash dividend payable June 14, 2024 to holders of record May 31, 2024.","Repurchased 0.3M shares for $1.9M in Q3; $22.3M remaining under buyback program; cash $17.4M, no debt."],"urls":{"canonical":"https://secwatch.observer/filing/0000849146-24-000048","json":"https://secwatch.observer/filing/0000849146-24-000048.json","markdown":"https://secwatch.observer/filing/0000849146-24-000048.md","text":"https://secwatch.observer/filing/0000849146-24-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/849146/000084914624000048/0000849146-24-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/849146/000084914624000048/lfvn-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T01:18:25.637031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a41ea2782eb57d79d7e8fb2e5ba6289cc6d233d","claim":"Lifevantage Corp reported three and nine months ended March 31, 2024 results: revenue $48.2 million, net income $1.7 million, EPS $0.13 per diluted share. Guidance lowered.","evidence_excerpt":"health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2024. Third Quarter Fiscal 2024 Summary*: • Revenue of $48.2 million, a decrease of 10.2% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue was down approximately 8.7%; • Revenue in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/849146/000084914624000048/0000849146-24-000048-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended March 31, 2024"},{"label":"Revenue","value":"$48.2 million"},{"label":"Net income","value":"$1.7 million"},{"label":"EPS","value":"$0.13 per diluted share"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}